Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries
- PMID: 10708941
- DOI: 10.1016/s0959-8049(99)00267-1
Long-term survival in Hodgkin's disease patients. A comparison of relative survival in patients in trials and those recorded in population-based cancer registries
Abstract
The prognosis of Hodgkins disease (HD) has improved during the last 30 years. This study was planned to analyse long-term survival of LID patients and to compare survival rates estimated from clinical trials and population-based data. Individual data were analysed on 2,755 adult HD patients entering randomised clinical trials of the British National Lymphoma Investigation BN LI) between 1970 and 1987, and 5,064 patients with HD incident 1978-1984 recorded in the UK population-based cancer registries participating in the EUROCARE study. Relative survival of Hodgkins disease patients allowing for mortality expected from general population rates was analysed by a proportional hazards regression model including covariates. Although relative mortality decreased with longer follow-up, it was still significantly positive at 9-10 years after diagnosis in both the clinical trials and the population-based data sets. Relative mortality was worse for late stage than for early stage patients even at 10-15 years after first treatment (BNLI data). Whereas 10-year relative survival was identical in trials and population-based patients at ages under 45 years (> 69%), it was much higher in BNLI older patients than in the population-based patients. In the older age group (65-74 years) the BNLI patients had 39% relative survival whilst for the population-based patients it was only 27%, Generalisation of clinical trials results to the general population must be done with caution, especially for older patients.
Similar articles
-
Late mortality in young BNLI patients cured of Hodgkin's disease.Ann Oncol. 1994;5 Suppl 2:65-6. doi: 10.1093/annonc/5.suppl_2.s65. Ann Oncol. 1994. PMID: 8204522
-
Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.J Clin Oncol. 2002 Apr 15;20(8):2101-8. doi: 10.1200/JCO.2002.08.021. J Clin Oncol. 2002. PMID: 11956271
-
Italian cancer figures, report 2012: Cancer in children and adolescents.Epidemiol Prev. 2013 Jan-Feb;37(1 Suppl 1):1-225. Epidemiol Prev. 2013. PMID: 23585445 English, Italian.
-
Hodgkin's and non-Hodgkin's lymphomas.Cancer Surv. 1994;19-20:423-53. Cancer Surv. 1994. PMID: 7534635 Review.
-
Treatment of Hodgkin's disease: results and current concepts of the German Hodgkin's Lymphoma Study Group.Ann Oncol. 2000;11 Suppl 1:81-5. Ann Oncol. 2000. PMID: 10707785 Review.
Cited by
-
Comparison of outcomes between Hodgkin's lymphoma patients treated in and outside clinical trials: A study based on the EORTC-Dutch late effects cohort-linked data.Eur J Haematol. 2023 Mar;110(3):243-252. doi: 10.1111/ejh.13899. Epub 2022 Nov 25. Eur J Haematol. 2023. PMID: 36369842 Free PMC article. Clinical Trial.
-
Lympho-hemopoietic malignancies in India.Med Oncol. 2002;19(3):141-50. doi: 10.1385/MO:19:3:141. Med Oncol. 2002. PMID: 12482124
-
Retrospective Multicenter Real-Life Study on the First-Line Treatment of Classical Hodgkin Lymphoma in Argentina.Clin Hematol Int. 2022 Jun 22;4(1-2):44-51. doi: 10.1007/s44228-022-00008-4. eCollection 2022 Jun. Clin Hematol Int. 2022. PMID: 35950206 Free PMC article.
-
Management of older Hodgkin lymphoma patients.Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):233-242. doi: 10.1182/hematology.2019000028. Hematology Am Soc Hematol Educ Program. 2019. PMID: 31808898 Free PMC article.
-
The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496.Br J Haematol. 2013 Apr;161(1):76-86. doi: 10.1111/bjh.12222. Epub 2013 Jan 29. Br J Haematol. 2013. PMID: 23356491 Free PMC article. Clinical Trial.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical